Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Xingaotuo Biotechnology

Request full access

AAV-mediated gene therapy restoring congenital hearing loss

ChinaFounded 2022Biotech & Life Sciences

About Xingaotuo Biotechnology

Xingaotuo Biotechnology, also known as Otovia Therapeutics, is a clinical-stage biotechnology company focused on developing gene therapies for genetic hearing loss. The company's primary area of research is the treatment of autosomal recessive deafness 9 (DFNB9), which is caused by mutations in the OTOFERLIN (OTOF) gene. This mutation prevents the production of the otoferlin protein, which is critical for transmitting sound signals from the inner ear to the brain.

The company's main product is an adeno-associated virus (AAV)-mediated gene therapy designed to deliver a healthy copy of the OTOF gene to the inner ear's cochlea. Due to the large size of the OTOF gene, the therapy utilizes a dual-vector approach, splitting the gene into two parts, which are then delivered via two separate AAVs. This treatment is administered via a direct injection into the fluid-filled cochlea. Clinical trials have shown promising results, with patients demonstrating significant hearing improvement within a month of treatment. In some cases, hearing has been restored to the normal range, allowing children who were previously deaf to hear conversational sounds and recognize speech.

Collaborating with institutions like Southeast University, the company has conducted clinical trials that have demonstrated both the safety and efficacy of their AAV-OTOF therapy in human patients. The research has progressed from successful preclinical studies in mice and non-human primates to treating children as young as 10 months old. More than 90% of children treated in the OTOF-based gene therapy trials have shown improved auditory skills. This work is considered a significant advancement, providing a proof-of-concept that may open the door for developing treatments for other forms of genetic deafness.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
19.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Neurology, Genetics and genomics, Pediatrics, Gene Therapy, Rare Diseases, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VC✓Equity / VC Jan 2026 $14M $55M Nanjing Innovation Capital · Fosun Health Capital · Dingxin Capital ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Xingaotuo Biotechnology in its local ecosystem

Live from Dealroom

The Xingaotuo Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • Nanjing Innovation Capital
  • Fosun Health Capital
  • Dingxin Capital
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Xingaotuo Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Xingaotuo Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.